2022 - Research.com Best Scientist Award
Member of the Association of American Physicians
His scientific interests lie mostly in Multiple myeloma, Cancer research, Internal medicine, Bone marrow and Bortezomib. His studies in Multiple myeloma integrate themes in fields like Hematology and Pathology. His Cancer research research integrates issues from Cell culture, Apoptosis, Protein kinase B, Cell growth and In vivo.
His Internal medicine research is multidisciplinary, incorporating elements of Gastroenterology, Endocrinology, Surgery and Oncology. The Bone marrow study combines topics in areas such as Molecular biology, Stromal cell, Immune system and Peripheral blood mononuclear cell. His Bortezomib research is multidisciplinary, relying on both Proteasome inhibitor, Proteasome, Cancer cell, Signal transduction and Stem cell.
Nikhil C. Munshi mainly focuses on Multiple myeloma, Cancer research, Internal medicine, Bortezomib and Bone marrow. The study incorporates disciplines such as Dexamethasone and Transplantation in addition to Multiple myeloma. Nikhil C. Munshi has included themes like Cell culture, Cell growth, Apoptosis, Cytotoxic T cell and In vivo in his Cancer research study.
His Internal medicine research is multidisciplinary, incorporating perspectives in Gastroenterology, Endocrinology, Surgery and Oncology. His Bortezomib study combines topics from a wide range of disciplines, such as Proteasome inhibitor, Proteasome and Pharmacology. His Bone marrow research incorporates elements of Monoclonal antibody, Stromal cell and Cytokine.
His primary scientific interests are in Multiple myeloma, Cancer research, Internal medicine, Oncology and Computational biology. Multiple myeloma is represented through his Bortezomib and Lenalidomide research. His biological study spans a wide range of topics, including Cell culture, Immune system, Immunotherapy, Antigen and Bone marrow.
The concepts of his Cell culture study are interwoven with issues in Apoptosis, microRNA and Cell growth. His study in the field of Cancer, Progression-free survival, Newly diagnosed and Veterans Affairs also crosses realms of In patient. His Oncology study incorporates themes from Relapsed refractory, Refractory Multiple Myeloma, Dexamethasone and Minimal residual disease.
Nikhil C. Munshi spends much of his time researching Multiple myeloma, Cancer research, Internal medicine, Oncology and Computational biology. Nikhil C. Munshi combines subjects such as MEDLINE, APOBEC, Disease, Regulation of gene expression and Bone marrow with his study of Multiple myeloma. His Bone marrow research incorporates themes from Stromal cell, Downregulation and upregulation and Stem cell.
Nikhil C. Munshi has researched Cancer research in several fields, including Cell culture, Cell growth, Antigen, B-Cell Maturation Antigen and Immunotherapy. His study in the fields of Cancer, Lenalidomide, Progression-free survival and Retrospective cohort study under the domain of Internal medicine overlaps with other disciplines such as In patient. His studies deal with areas such as Maintenance therapy and Bortezomib as well as Lenalidomide.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov;Serena Nik-Zainal;Serena Nik-Zainal;David C. Wedge;Samuel A. J. R. Aparicio.
Antitumor activity of thalidomide in refractory multiple myeloma.
Singhal S;Mehta J;Desikan R;Ayers D.
The New England Journal of Medicine (1999)
Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.
Robert C. Flanigan;Sydney E. Salmon;Brent A. Blumenstein;Scott I. Bearman.
The New England Journal of Medicine (2001)
Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts
E. Papaemmanuil;M. Cazzola;J. Boultwood;L. Malcovati.
The New England Journal of Medicine (2011)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar;Bruno Paiva;Kenneth C. Anderson;Brian Durie.
Lancet Oncology (2016)
NF-κB as a Therapeutic Target in Multiple Myeloma *
Teru Hideshima;Dharminder Chauhan;Paul Richardson;Constantine Mitsiades.
Journal of Biological Chemistry (2002)
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Jan Krönke;Namrata D. Udeshi;Anupama Narla;Peter Grauman.
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
Paul G. Richardson;Edie Weller;Sagar Lonial;Andrzej J. Jakubowiak.
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.
Nicholas Mitsiades;Constantine S. Mitsiades;Paul G. Richardson;Vassiliki Poulaki.
Molecular sequelae of proteasome inhibition in human multiple myeloma cells
Nicholas Mitsiades;Constantine S. Mitsiades;Vassiliki Poulaki;Dharminder Chauhan.
Proceedings of the National Academy of Sciences of the United States of America (2002)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: